Literature DB >> 33095929

Liver complications of haemoglobin H disease in adults.

Luke K L Chan1, Vivien W M Mak1, Stanley C H Chan2, Ellen L M Yu3, Nelson C N Chan4, Kate F S Leung5, Carmen K M Ng6, Margaret H L Ng4, Joyce C W Chan1, Harold K K Lee1.   

Abstract

Haemoglobin H (HbH) disease is a type of non-transfusion-dependent thalassaemia. This cross-sectional study aimed at determining the prevalence and severity of liver iron overload and liver fibrosis in patients with HbH disease. Risk factors for advanced liver fibrosis were also identified. A total of 80 patients were evaluated [median (range) age 53 (24-79) years, male 34%, non-deletional HbH disease 24%]. Patients underwent 'observed' T2-weighted magnetic resonance imaging examination for liver iron concentration (LIC) quantification, and transient elastography for liver stiffness measurement (LSM) and fibrosis staging. In all, 25 patients (31%) had moderate-to-severe liver iron overload (LIC ≥7 mg/g dry weight). The median LIC was higher in non-deletional than in deletional HbH disease (7·8 vs. 2.9 mg/g dry weight, P = 0·002). In all, 16 patients (20%) had advanced liver fibrosis (LSM >7.9 kPa) and seven (9%) out of them had probable cirrhosis (LSM >11.9 kPa). LSM positively correlated with age (R = 0·24, P = 0·03), serum ferritin (R = 0·36, P = 0·001) and LIC (R = 0·28, P = 0·01). In multivariable regression, age ≥65 years [odds ratio (OR) 4·97, 95% confidence interval (CI) 1·52-17·50; P = 0·047] and moderate-to-severe liver iron overload (OR 3·47, 95% CI 1·01-12·14; P = 0·01) were independently associated with advanced liver fibrosis. The findings suggest that regular screening for liver complications should be considered in the management of HbH disease.
© 2020 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  haemoglobin H disease; iron overload; liver disease; thalassaemia

Year:  2020        PMID: 33095929     DOI: 10.1111/bjh.17115

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  1 in total

Review 1.  Thalassemia Intermedia: Chelator or Not?

Authors:  Yen-Chien Lee; Chi-Tai Yen; Yen-Ling Lee; Rong-Jane Chen
Journal:  Int J Mol Sci       Date:  2022-09-05       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.